Business Context and Reporting Period
Tenon Medical, Inc. (Tenon), an emerging growth company incorporated in Delaware, filed this Form 8-K on March 25, 2025, to report the entry into a material definitive agreement. The company is headquartered in Los Gatos, California, and its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols TNON and TNONW, respectively.
Key Financial Metrics and Transaction Details
The filing details a Registered Direct Offering and Concurrent Private Placement that closed on March 27, 2025. Key financial terms include:
- Gross Proceeds: Approximately $2.54 million.
- Securities Issued:
- 615,000 shares of Common Stock.
- Pre-funded warrants to purchase up to 656,500 shares of Common Stock.
- Common warrants to purchase an aggregate of 1,271,500 shares of Common Stock with an exercise price of $2.00.
- Placement Agent Fees: A cash fee of 7.0% of aggregate gross proceeds, plus reimbursement of out-of-pocket expenses up to $50,000.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels, as this is a current report regarding a capital raise rather than a periodic financial statement.
Material Changes and Transaction Structure
The primary material change is the dilution of existing shareholders due to the issuance of new equity and warrants. The transaction structure includes:
- Registered Direct Offering: Issued pursuant to a shelf registration statement on Form S-3 (File No. 333-271648).
- Private Placement: Common warrants were issued under Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act of 1933.
- Lock-Up Provisions: Tenon agreed not to issue additional Common Stock or equivalents for 60 days following the effectiveness of the Resale Registration Statement, with an exception for "at the market offerings" expiring 15 days after the closing date.
Outlook, Risks, and Management Commentary
Management has committed to filing a resale registration statement on Form S-1 or S-3 within 30 calendar days of the Purchase Agreement to register the resale of Common Warrant Shares. The Common Warrants are exercisable immediately and will expire on the fifth anniversary of issuance. A.G.P./Alliance Global Partners acted as the exclusive placement agent on a "reasonable best efforts" basis. The filing notes a "bring-over-the-wall" provision where Tenon must pay the placement agent the same consideration if it sells securities to a party introduced by the agent within six months of the closing.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 7.0% placement fee and the $50,000 expense cap.
- Confirm the dilution impact of the 615,000 shares, 656,500 pre-funded warrant shares, and 1,271,500 common warrant shares on the current share count.
- Monitor the filing and effectiveness date of the Resale Registration Statement for the Common Warrants.
- Review the definitive Securities Purchase Agreement (Exhibit 10.1) for specific covenants and exceptions to the lock-up period.
- Assess the company's cash runway post-transaction given the $2.54 million gross raise.